The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives

Carconi, Catia; Cerreti, Micaela; Roberto, Michela; Arrivi, Giulia; D’Ambrosio, Giancarlo; Felice, Francesca De; Civita, Mattia Alberto Di; Iafrate, Franco; Lucatelli, Pierleone; Magliocca, Fabio Massimo; Picchetto, Andrea; Picone, Vincenzo; Catalano, Carlo; Cortesi, Enrico; Tombolini, Vincenzo; Mazzuca, Federica; Tomao, Silverio

doi:10.1016/j.critrevonc.2023.103990

Cited by 3 publications

(3 citation statements)

References 251 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent publication on oligometastatic disease in CRC found that oligometastatic disease was described as an intermediate clinical state between localized cancer and systemically metastasized disease, and prolonged survival might be achieved when aggressive locoregional approaches were added to systemic therapies for patients with oligometastatic disease in CRC. 45 Although the definition of oligometastatic disease in CRC remained controversial currently, it seemed that the most widely accepted definition of oligometastatic CRC manifested as up to 5 lesions in no more than 3 metastatic sites which typically involve the liver, lung and lymph nodes and absence of ascites and peritoneal, bone and central nervous system metastases in clinical practice currently. 46 Oligometastatic CRC might achieve superior prognosis if all metastatic lesions were resected or destructed using techniques such as surgery, radiofrequency ablation, stereotactic radiotherapy or TACE, especially when patients were live or lung metastasis.…”

Section: Discussionmentioning

confidence: 99%

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study

Bai,

Wang,

Zhou

et al. 2024

CMAR

View full text Add to dashboard Cite

Objective Therapeutic regimens are relatively scarce among patients with treatment-refractory metastatic colorectal cancer (CRC). This study aimed to determine the feasibility and tolerability of anlotinib plus PD-1 blockades in patients with treatment-refractory metastatic CRC retrospectively. Methods A total of 68 patients with previously treated metastatic CRC who received anlotinib plus PD-1 blockades in clinical practice were included in this study retrospectively. Demographic and clinical characteristics of the patients, therapeutic outcomes and safety profile during administration were collected and briefly analyzed. All subjects were followed up regularly. Therapeutic outcomes, including drug response and prognosis, were presented, and a safety profile was depicted to illustrate the adverse reactions. Results A total of 68 patients with treatment-refractory metastatic CRC who received anlotinib plus PD-1 blockades in clinical practice were included in the final analysis. Best therapeutic response during treatment indicated that partial response was observed in 11 patients, stable disease was noted in 41 patients, and progressive disease was found in 16 patients, producing an objective response rate of 16.2% (95% CI: 8.4%–27.1%) and a disease control rate of 76.5% (95% CI: 64.6%–85.9%). Prognostic analysis suggested that the median progression-free survival (PFS) of the 68 patients was 5.3 months (95% CI: 3.01–7.59), and the median overall survival (OS) was 12.5 months (95% CI: 9.40–15.60). Of the 11 patients who responded, the median duration of response was 6.7 months (95% CI: 2.89–10.53). Safety profile during treatment showed that patients experienced adverse reactions regardless of grade, and grade ≥3 adverse reactions were found in 61 patients (89.7%) and 41 patients (60.3%), respectively. Common adverse reactions were hypertension, myelosuppression (including leukopenia, neutropenia, thrombocytopenia, and anemia), fatigue, and hand-foot syndrome. Conclusion Anlotinib plus PD-1 blockades demonstrated encouraging efficacy and acceptable safety profile in patients with treatment-refractory metastatic CRC preliminarily in clinical practice. This conclusion should be confirmed in prospective clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study

Bai,

Wang,

Zhou

et al. 2024

CMAR

View full text Add to dashboard Cite

show abstract

“…Repeat hepatic resection is also justified, as is resection in the presence of oligometastatic disease. 36 , 37 Regional lymphadenectomy also has a place, particularly as lymph node involvement is easy to overestimate. 38 , 39 Sometimes, this may involve combined resection of the extrahepatic biliary tree (Figure 4 ), although this is not usually needed.…”

Section: Surgical Decision Makingmentioning

confidence: 99%

“…Recent clinical studies have shown prolonged survival when aggressive locoregional approaches are added to systemic therapies in patients with oligometastases. 37 …”

Section: Oligometastatic Diseasementioning

confidence: 99%

New trends in surgery for colorectal liver metastasis

Kron,

Lodge

2024

Annals of Gastroent Surgery

View full text Add to dashboard Cite

By presenting the most up‐to‐date findings and incorporating the latest evidence, this article seeks to present a comprehensive guide for navigating the complexities inherent in the management of colorectal liver metastasis. It aims to serve as a valuable resource offering clinicians and healthcare professionals an understanding of the diverse modalities and approaches available for treating this challenging and multifaceted disease. In an era of rapidly evolving medical knowledge, this article examines the latest insights to make informed decisions in the realm of colorectal liver metastasis management. The article does not only highlight the up‐to‐date knowledge but also provides the evidence for existing therapeutic strategies. This practical tool provides evidence‐based recommendations to clinicians, thereby contributing to the ongoing advancement of effective treatment strategies for this challenging disease.

show abstract

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Dooper

2024

Medicom Conference Report ASCO 2024

View full text Add to dashboard Cite

The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives

Cited by 3 publications

References 251 publications

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study

New trends in surgery for colorectal liver metastasis

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Contact Info

Product

Resources

About